Figure 2: Novel Incretin Mimetic Assets for T2DM and Obesity in Phase 2/3 of Development Remaining Unmet Needs Remaining Unmet Needs Though the value proposition of on-market GLP-1 and dual-agonists is strong, several key unmet needs still exist for incretin mimetics across diabetes and obesity, namely: (1) improved efficacy, (2) better tolerability, (3) more convenient options / alternative ROAs, and (4) improved access and affordability
Han, Y., Kim, S., Park, T., Hwang, H., Park, S., Kim, J., et al
BPC-157 is also known as the Wolverine peptide, for its ability to help support repair and recovery, many have also found that its helped support gut issues, gastric reflux, depression, performance, and more
If youre insured: Know which GLP-1s your plan covers : Some plans may only cover certain ones for specific indications, i.e